Amgen Inc. is expanding its early clinical pipeline with the addition of a CCR4 antibody licensed from Kyowa Hakko Kogyo Co. Ltd. in exchange for $100 million up front and up to $420 million in milestones. (BioWorld Today)
Shares of Renovo plc tumbled 51 percent after its anti-scarring product, Juvista, missed its endpoint in a Phase II trial in patients undergoing breast augmentation surgery, leading investors to worry about the product's chances for broad label approval. (BioWorld Today)
Shares of Renovo plc tumbled 51 percent after its anti-scarring product, Juvista, missed its endpoint in a Phase II trial in patients undergoing breast augmentation surgery, leading investors to worry about the product's chances for broad label approval. (BioWorld Today)
In the wake of the FDA's second rejection of non-small-cell lung cancer candidate Xcytrin, Pharmacyclics Inc. is slashing its work force by 40 percent and refocusing resources on its earlier-stage pipeline in cancer and immune-mediated diseases. (BioWorld Today)
In the wake of the FDA's second rejection of non-small-cell lung cancer candidate Xcytrin, Pharmacyclics Inc. is slashing its work force by 40 percent and refocusing resources on its earlier-stage pipeline in cancer and immune-mediated diseases. (BioWorld Today)
